About Fomicyt® (fosfomycin IV)

Fomicyt® (fosfomycin IV) is a valuable agent for the treatment of patients at high risk of acquiring resistant pathogens in initial empirical combination therapy, for targeted combination therapy in difficult-to-treat or deep-seated infections, or as rescue therapy in patients with or without multidrug-resistant pathogens.

Fomicyt® (fosfomycin IV) therapy is primarily used in combination therapy in difficult-to-treat infections caused by Gram-negative and Gram positive pathogens, including E.coli (Escherichia coli), Staphylococcus aureus, Enterococcus faecalis and Klebsiella pneumoniae. It is often used in monotherapy in complicated urinary tract infections.

Fomicyt® (fosfomycin IV) can also be used in combination therapy with other antibiotic agents for many other indications, such as acute and chronic osteomyelitis, nosocomial lower respiratory tract infections (HAP/VAP) and bacteraemia/sepsis of unknown origin, or occurring in association with or suspected to be associated with the infections mentioned above.

Fomicyt 40 mg/ml
Fomicyt 40 mg/ml

Legal Category: POM – Prescription only medicine.

Fight your severe infections, hit hard and early with Fomicyt® (fosfomycin IV)

Fight Your Severe Infections

*   including serum, kidneys, bladder, prostate, lungs, inflamed tissues, bone, muscle, eye, cerebrospinal fluid, abscess fluid, aqueous humour and heart valves 2-4

  1. eMC; IV Summary of Product characteristics
    You are leaving
    You are now leaving fomicyt.co.uk
    This link takes you to a third party website (outside of the Fomicyt® UK website). InfectoPharm Ltd has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the application laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites. If you wish to continue, click ‘CONTINUE’, or otherwise click ‘Stay on page’ -->
    CONTINUE
    Stay On Page
    Fomicyt® IV Summary of Product characteristics accessed July 2025.
  2. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.
  3. Castañeda-García A et al. Antibiotics 2013;2:217-236.
  4. Joukhadar C, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003;51:1247–1252;
  5. Schintler MV, et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother. 2009;64(3):574-8;
  6. Kuhnen E, et al. Penetration of fosfomycin into cerebrospinal _uid across non-in_amed and in_amed meninges. Infection. 1987;15(6):422–4;
  7. Matzi V, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother. 2010;65:995–998;
  8. Hirt SW, et al. Perioperative preventive antibiotic treatment with fosfomycin in heart surgery: Serum kinetics in extracorporeal circulation and determination of concentration in heart valve tissue. Z Kardiol. 1990;79(9):615–20;
  9. Sauermann R, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time pro_les. Antimicrob Agents Chemother. 2005;49:4448–4454